Planer D, Lev I, Elitzur Y, Sharon N, Ouzan E, Pugatsch T, Chasid M, Rom M, Lotan C. Bupropion for smoking cessation in patients with acute coronary syndrome. Arch Intern Med. 2011;171:1055 1060. doi: 10.1001/archinternmed.2011.72. 312. Tonstad S, Farsang C, Klaene G, Lewis K, Manolis A, Perruchoud AP, Silagy C, van Spiegel PI, Astbury C, Hider A, Sweet R. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multi- centre, randomised study. Eur Heart J. 2003;24:946 955. 313. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56 63. doi: 10.1001/jama.296.1.56. 314. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K. Efficacy and safety of the novel selective nic- otinic acetylcholine receptor partial agonist, varenicline, for smok- ing cessation. Arch Intern Med. 2006;166:1571 1577. doi: 10.1001/ archinte.166.15.1571. 315. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010;121:221 229. doi: 10.1161/CIRCULATIONAHA.109.869008. 316. Steinberg MB, Schmelzer AC, Richardson DL, Foulds J. The case for treating tobacco dependence as a chronic disease. Ann Intern Med. 2008;148:554 556. 317. Hansen D, Dendale P, Leenders M, Berger J, Raskin A, Vaes J, Meeusen R. Reduction of cardiovascular event rate: different effects of cardiac rehabilitation in CABG and PCI patients. Acta Cardiol. 2009;64:639 644. 318. Hedb ck B, Perk J, H rnblad M, Ohlsson U. Cardiac rehabilitation after coronary artery bypass surgery: 10-year results on mortality, morbidity and readmissions to hospital. J Cardiovasc Risk. 2001;8:153 158. 319. 